We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Immune Tolerance Level Predicts Leukemia Outcome

By LabMedica International staff writers
Posted on 04 Dec 2017
Print article
Image: A representation of the molecular structure of the Indoleamine 2,3 dioxygenase-1 (IDO-1) protein (Photo courtesy of Wikimedia Commons).
Image: A representation of the molecular structure of the Indoleamine 2,3 dioxygenase-1 (IDO-1) protein (Photo courtesy of Wikimedia Commons).
Measurement of messenger RNA (mRNA) encoding an enzyme that augments tumor-induced immune tolerance was shown to be predicative of the outcome for patients with leukemia.

Indoleamine 2,3 dioxygenase-1 (IDO-1) is an enzyme in the kynurenine pathway that augments tumor-induced immune tolerance. Previous studies in childhood acute myeloid leukemia (AML) have shown a negative correlation of IDO-1 mRNA expression with outcomes. In other words, increased IDO expression in bone marrow biopsies correlated with lower overall survival rates and early mortality.

Investigators at the Medical College of Georgia at Augusta University, USA) set out to develop a practical and objective immunohistochemical technique to quantify IDO-1 expression on diagnostic bone marrow biopsies of AML patients in order to facilitate its use in routine clinical practice.

In establishing the procedure, the investigators extracted IDO-1 mRNA from diagnostic bone marrow specimens from 29 AML patients. IDO-1 protein expression was assessed in 40 cases via immunohistochemistry and quantified by a novel "composite IDO-1 score."

Results revealed that a higher composite IDO-1 score could accurately predict poor outcomes. Further, patients who failed induction therapy (chemotherapy for AML) had higher composite IDO-1 scores. Therefore, the "composite IDO-1 score" was demonstrated to be a prognostic tool that could help identify a certain subset of AML patients with "early mortality." This unique subset of patients could potentially benefit from specific IDO-1 inhibitor therapy, currently in clinical trials.

"We want to help people who are not responding to treatment and are dying very soon after their diagnosis," said senior author Dr. Ravindra Kolhe, associate professor of pathology at the Medical College of Georgia at Augusta University. "Most of the time, we do not know why patients are not responding to chemotherapy. Right now we know it is high in patients who die at six months and we show that it is an independent indicator if you adjust for other known variables."

The study was published in the October 16, 2017, online edition of the journal Scientific Reports.

Related Links:
Medical College of Georgia at Augusta University

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: A false color scanning election micrograph of lung cancer cells grown in culture (Photo courtesy of Anne Weston)

AI Tool Precisely Matches Cancer Drugs to Patients Using Information from Each Tumor Cell

Current strategies for matching cancer patients with specific treatments often depend on bulk sequencing of tumor DNA and RNA, which provides an average profile from all cells within a tumor sample.... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more

Pathology

view channel
Image: Fingertip blood sample collection on the Babson Handwarmer (Photo courtesy of Babson Diagnostics)

Unique Hand-Warming Technology Supports High-Quality Fingertip Blood Sample Collection

Warming the hand is an effective way to facilitate blood collection from a fingertip, yet off-the-shelf solutions often do not fulfill laboratory requirements. Now, a unique hand-warming technology has... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.